Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2018-06-28
|
IFX-1 |
ANCA-associated vasculitis (AAV) |
2 |
InflaRx (Germany) |
Autoimmune diseases - Cardiovascular diseases - Rare diseases |
2018-06-27
|
Emgality™ (galcanezumab-gnlm - LY2951742) |
episodic migraine, chronic migraine |
3 |
Eli Lilly (USA - IN) |
CNS diseases - Neurological diseases |
2018-06-26
|
AT-GAA (ATB200/AT2221) |
Pompe disease |
1-2 |
Amicus Therapeutics (USA - NJ) |
Genetic diseases - Rare diseases - Metabolic diseases |
2018-06-25
|
GNbAC1 |
type 1 diabetes |
preclinical |
Geneuro (Switzerland) |
Autoimmune diseases - Metabolic diseases |
2018-06-25
|
G100 |
indolent non-Hodgkin Follicular lymphomas (FL) |
preclinical |
Immune Design (USA - MA) |
Cancer - Oncology |
2018-06-20
|
aprocitentan |
resistant hypertension management in adults |
3 |
Idorsia (Switzerland) |
Cardiovascular diseases |
2018-06-18
|
clazosentan |
prevention of clinical deterioration due to vasospasm-related delayed cerebral ischemia in patients following an aneurysmal subarachnoid hemorrhage |
3 |
Idorsia (Switzerland) |
Cerebrovascular diseases |
2018-06-18
|
remetinostat |
early-stage cutaneous T-cell lymphoma (CTCL). |
3 |
Medivir (Sweden) |
Cancer - Oncology |
2018-06-18
|
remetinostat |
early-stage cutaneous T-cell lymphoma (CTCL). |
3 |
Medivir (Sweden) |
Cancer - Oncology |
2018-06-15
|
LentiGlobin® BB305 (autologous CD34+ haematopoietic stem cells transduced with lentiviral vector encoding the human beta A-T87Q-globin gene) |
transfusion-dependent beta-thalassemia with non-Beta0/Beta0 genotypes |
3 |
Bluebird bio (USA - MA) |
Rare diseases - Genetic diseases - Hematological diseases |
2018-06-15
|
LentiGlobin® BB305 (autologous CD34+ haematopoietic stem cells transduced with lentiviral vector encoding the human beta A-T87Q-globin gene) |
beta-thalassemia |
1-2 |
bluebird bio (USA - MA) |
Hematologic diseases - Genetic diseases - Rare diseases |
2018-06-15
|
LentiGlobin® BB305 (autologous CD34+ haematopoietic stem cells transduced with lentiviral vector encoding the human beta A-T87Q-globin gene) |
sickle cell disease |
1 |
bluebird bio (USA - MA) |
Genetic diseases - Hematological diseases - Rare diseases |
2018-06-12
|
CubiCAR |
|
preclinical |
Cellectis (France) |
|
2018-06-04
|
Ad-RTS-hIL-12 + veledimex - adenoviral vector-RheoSwitch Therapeutic System-human interleukin 12 + veledimex |
patients with recurrent or progressive glioblastoma or Grade III malignant glioma |
1 |
Ziopharm Oncology (USA - MA) |
Cancer - Oncology - Rare diseases |
2018-06-04
|
Ad-RTS-hIL-12 + veledimex - adenoviral vector-RheoSwitch Therapeutic System-human interleukin 12 + veledimex |
patients with locally advanced or metastatic breast cancer |
1b-2 |
Ziopharm Oncology (USA - MA) |
Cancer - Oncology |
2018-06-04
|
RE-024 Fosmetpantotenate |
pantothenate kinase-associated neurodegeneration (PKAN) |
3 |
Retrophin (USA - CA) |
Rare diseases - Genetic diseases - Neurological diseases |
2018-06-04
|
epacadostat and nivolumab |
advanced solid tumors and lymphomas, including melanoma (MEL), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), squamous cell carcinoma of the head and neck (SCCHN), ovarian cancer (OC), and B cell non-Hodgkin lymphoma ( NHL ) or Hodgkin lymphoma (HL) |
1-2 |
BMS (USA - NY) Incyte (USA - DE) |
Cancer - Oncology |
2018-06-03
|
durvalumab (MEDI4736) and monalizumab (IPH2201/anti-NKG2A) |
advanced solid tumors |
1 |
AstraZeneca (UK) Innate Pharma (France) |
Cancer - Oncology |
2018-06-03
|
tazemetostat - EPZ-6438 (E7438) |
relapsed/refractory malignant mesothelioma patients with BRCA1-associated protein 1 (BAP1) loss-of-function |
2 |
Epizyme (USA - MA) |
Cancer - Oncology - Rare diseases |
2018-06-01
|
bb2121 anti-BCMA CAR T cells |
multiple myeloma |
1 |
Bluebird bio (USA - MA) Celgene (USA - NJ) |
Cancer - Oncology |